Treatment response and side effects of venlafaxine were evaluated in an open-label trial of elderly outpatients with dysthymic disorder (DD). Patients received flexible dose (up to 300 mg/d) venlafaxine (Effexor XR) for 12 weeks. Of 23 study patients, 18 completed the trial. Fourteen (60.9%) were responders in intent-to-treat analyses with the last observation carried forward, and 77.8% were responders in completer analyses. Nearly half the sample (47.8%) met criteria for remission. In the intent-to-treat sample, increased severity of depression at baseline was associated with superior response, and the presence of cardiovascular disease was associated with poorer response. Venlafaxine open-label treatment was associated with fairly high response rates and generally good tolerability in elderly patients with DD. These results indicate that in elderly patients with DD, placebo-controlled trials of a dual reuptake inhibitor such as venlafaxine would be needed to assess its efficacy or to compare its efficacy to that of other antidepressants.
1. Blazer D, Hughes DC, George LK. The epidemiology of depression in an elderly community population. Gerontologist. 1987; 27:281-287.
2.
2. Stefansson JG, Lindal E, Bjornsson JK, Guomundsdottir A.Lifetime prevalence of specific mental disorders among people born in Iceland in 1931. Acta Psychiatr Scand.1991;84:142-149.
3.
3. Devanand DP, Nobler MS, Singer T, et al. Is dysthymia a different disorder in the elderly?Am J Psychiatry. 1994;151:1592-1599.
4.
4. Devanand DP, Turret N, Moody BJ, et al. Personality disorders in elderly patients with dysthymic disorder. Am J Geriatr Psychiatry. 2000;8:188-195.
5.
5. Reynolds CF, Frank E, Kupfer DJ, et al. Treatment outcome in recurrent major depression: a post hoc comparison of elderly (“young old”) and midlife patients. Am J Psychiatry. 1996;153:1317-1324.
6.
6. Abrams RC, Spielman LA, Alexopoulos GS, Klausner E.Personality disorder symptoms and functioning in elderly depressed patients. Am J Geriatr Psychiatry. 1998;6:24-30.
7.
7. Olfson M, Marcus SC, Pincus HA, et al. Antidepressant prescribing practices of outpatient psychiatrists. Arch Gen Psychiatry. 1998;55:310-316.
8.
8. Shelton RC, Davidson J, Yonkers KA, et al. The undertreatment of dysthymia. J Clin Psychiatry. 1997;58:59-65.
9.
9. Devanand DP, Nobler MS, Cheng J, et al. A randomized, doubleblind, placebo-controlled, trial of fluoxetine treatment for elderly patients with dysthymic disorder. Am J Geriatr Psychiatry. In press.
10.
10. Williams JW Jr, Barrett J, Oxman T, et al. Treatment of dysthymia and minor depression in primary care: a randomized controlled trial in older adults. JAMA. 2000;284:1519-1526.
11.
11. Hellerstein DJ, Batchelder ST, Lee A, Borisovskaya M.Rating dysthymia: an assessment of the construct and content validity off the Cornell dysthymia rating scale. J Affect Disord. 2002;71:85-96.
12.
12. Kocsis JH, Frances AJ, Voss C, et al. Imipramine treatment for chronic depression. Arch Gen Psychiatry. 1988;45:253-257.
13.
13. Vanelle J, Attar-Levy D, Poirier M, et al. Controlled efficacy study of fluoxetine in dysthymia. Br J Psychiatry. 1997;170:345-350.
14.
14. de Lima MS, Hotoph M, Wessely S.The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis. Psychol Med.1999;29:1273-1289.
15.
15. Thase ME, Fava M, Halbreich U, et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry. 1996;53:777-784.
16.
16. Ravindran AV, Guelfi JD, Lane RM, Cassano GB. Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. J Clin Psychiatry. 2000;61:821-827.
17.
17. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
19. Ravindran AV, Charbonneau Y, Zaharia MD, et al. Efficacy and tolerability of venlafaxine in the treatment of primary dysthymia. J Psychiatry Neurosci. 1998;23:288-292.
20.
20. Ballus C, Quiros G, De Flores T, et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol. 2000;15:43-48.
21.
21. Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric patients and research: application of the Cumulative Illness Rating Scale. Psychiatry Res.1992;41:237-248.
22.
22. Ventura J, Liberman RP, Green MF, Shaner A, Mintz J.Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Res.1998;79:163-173.
23.
23. Mason BJ, Kocsis JH, Leon AC, et al. Measurement of severity and treatment response in dysthymia may have been limited by the structure and format of existing rating instruments. Psychiatr Ann.1993;23:625-631.
24.
24. Fawcett J, Epstein P, Fiester SJ, et al. Clinical managementimipramine/placebo administration manual. NIMH Treatment of Depression Collaborative Research Program. Psychopharmacol Bull.1987;23:309-324.
25.
25. Nobler MS, Devanand DP, Kim MK, et al. Fluoxetine treatment of dysthymia in the elderly. J Clin Psychiatry. 1996;57:254-256.
26.
26. Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry. 1997;58:393-398.
27.
27. Nyth AL, Gottfries CG, Lyby K, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand. 1992;86:138-145.
28.
28. Tollefson GD, Holman SL. Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression. Int Clin Psychopharmacol. 1993;8:253-259.
29.
29. Schneider L, Clary C, Finkel S, et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry. 2003;160:1277-1285.
30.
30. Finkel SI, Richter EM, Clary CM. Comparative efficacy and safety of sertraline versus nortriptyline in major depression in patients 70 and older. Int Psychogeriatr. 1999;11:85-99.
31.
31. Mulsant BH, Pollock BG, Nebes R, et al. A twelve-week, doubleblind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. Am J Geriatr Psychiatry. 2001;9:406-414.
32.
32. Hickie I, Scott E, Wilhelm K, Brodaty H.Subcortical hyperintensities on magnetic resonance imaging in patients with severe depression: a longitudinal evaluation. Biol Psychiatry. 1997;42:367-374.
33.
33. Krishnan KR, Hays JC, George LK, Blazer DG. Six-month outcomes for MRI-related vascular depression. Depress Anxiety. 1998;8:142-146.
34.
34. Miller MD, Lenze EJ, Dew MA, et al. Effect of cerebrovascular risk factors on depression treatment outcome in later life. Am J Geriatr Psychiatry. 2002;10:592-598.
35.
35. Alexopoulos GS, Meyers BS, Young RC, et al. Executive dysfunction and risk for relapse and recurrence of geriatric depression. Arch Gen Psychiatry. 2000;57:285-290.
